Elutia And Advantus Collaborate To Expand Market Reach For EluPro™, FDA-Approved, Antibiotic-Eluting BioEnvelope

Elutia Inc., a leader in drug-eluting biomatrix technology, has entered into a strategic agreement with Advantus Health Partners to provide access to its EluPro™ Antibiotic Eluting BioEnvelope through Advantus’ group purchasing organization (GPO) solutions portfolio.

“Teaming up with Advantus is another major step forward in meeting the strong customer demand for EluPro,” said Dr. Kimberly Mulligan, GM and VP of Elutia’s Cardiovascular Division. “Our pilot launch of EluPro has exceeded our expectations as physicians recognize the unique value that this antibiotic envelope brings in preventing infection for patients that use a cardiac implantable electronic device. Broadening our GPO coverage with Advantus allows us to benefit from their sustainable contracting solutions, making EluPro more widely available to physicians nationwide.”

EluPro™ is the first and only FDA-cleared antibiotic-eluting biologic envelope designed for cardiac implantable electronic devices (CIEDs) and neurostimulators. The product integrates antibiotics with a natural extracellular matrix that regenerates into the patient’s own tissue, aiming to reduce infection risk, prevent migration, and minimize skin erosion post-surgery. With this new collaboration, Elutia has now partnered with seven major national GPOs, further expanding its market reach.

Advantus Health Partners optimizes healthcare supply chains through its purchasing efficiency and cost-saving initiatives, along with service operation enhancements. Simplifying healthcare costs across the nation remains the core mission of the company through its innovative contracting methods and business models designed for the financial success of healthcare organizations.